Indian Ustekinumab Exporters: Complete Supplier Ranking with Market Share — 78 Manufacturers (2026) — TransData Nexus

Q: Who is the largest ustekinumab buyer importing from India?

AS PER INVOICE BRAZIL (BRAZIL) is the largest ustekinumab importer from India with a 8.8% market share and import value of $112.2K.

Q: How many ustekinumab buyers import from India?

There are 78 active ustekinumab buyers importing from India, with a combined import market of $1.3M across 276 shipments according to Indian Customs (DGFT) records.

Q: What is the market share of top ustekinumab buyers from India?

The top 5 ustekinumab buyers — AS PER INVOICE BRAZIL, SHIMA HIROMI, TO THE CONCERN PERSON, TO THE CONSIGNEE-, NEUSA ALVES DA SILVA — together control 27.5% of total ustekinumab import value from India.

Suresh Sormare

Ustekinumab

India Pharmaceutical Trade Intelligence

$1.3M23 Suppliers10 CountriesHS 30021500

ExportsIndia → BRAZIL71.5%India → JAPAN12.6%

ImportsNETHERLANDS → India$1.5M UNITED STATES → India$1.1M

#1 Supplier: NIVIRA EXPORTS #1 Buyer: AS PER

Market Analysis: Top Importing Countries & Their Importers

1Brazil

Brazil emerges as the first largest importing country, achieving a total trade value of $909.9K through 77 shipments. This represents a market share of 71.5% of the total market activity, demonstrating their significant presence in the industry.

Top Importers: Brazil has a diverse importer base, with their top importers including:

• AS PER INVOICE BRAZIL - $112.2K (12.3% of country's total business)

• TO THE CONCERN PERSON - $56.2K (6.2% of country's total business)

• NEUSA ALVES DA SILVA - $29.7K (3.3% of country's total business)

• ISIS DE OLIVEIRA MELO FELTRIN - $24.1K (2.6% of country's total business)

• FABIO ROSA VACCARI - $15.0K (1.6% of country's total business)

• Rest of Brazil's importers - $672.6K (73.9% of country's total business)

Key Insight: Brazil demonstrates strong market positioning with an average shipment value of $11.8K, indicating premium pricing strategy compared to the market average of $4.6K.

Brazil is a key market for Ustekinumab imports, representing 71.5% of total trade value.

Primary Market

Secondary Market

Buyer Segment Analysis

TransData Nexus Ustekinumab buyer market intelligence

1Buyer Segment Analysis

Our data indicates that Ustekinumab exports from India amounted to $1.3 million across 276 shipments, involving 23 exporters and 78 buyers across 10 importing countries. The repeat buyer rate stands at 42.3%, suggesting a significant proportion of buyers engage in multiple transactions.

Buyer Segments:

1. Distributors: Entities such as "IMPORT MANAGER INTERNATIONAL SALES CO" in Turkey and "DAWAA DRUG STORE LLC" in the United Arab Emirates likely function as distributors. These organizations typically purchase large quantities to supply regional markets, maintaining consistent order patterns to meet ongoing demand.

2. Hospital Groups: While specific hospital groups are not explicitly identified in the top buyers, it's plausible that some buyers represent hospital procurement departments. These entities usually place orders based on patient needs and treatment protocols, leading to periodic bulk purchases.

3. Retail Chains: Individual buyers such as "SHIMA HIROMI" in Japan and "NEUSA ALVES DA SILVA" in Brazil may represent retail pharmacies or small chains. Their purchasing behavior often involves smaller, more frequent orders to manage inventory effectively.

4. Government Procurement: The data does not explicitly mention government agencies like UNICEF or national health departments. However, in markets with centralized healthcare systems, government tenders can lead to substantial, less frequent orders aligned with budget cycles and public health initiatives.

5. Re-exporters: Buyers such as "TO THE CONCERN PERSON" in Brazil and "TO THE CONSIGNEE-" in Saudi Arabia may act as intermediaries, purchasing Ustekinumab for re-export to neighboring regions. Their order patterns can be irregular, influenced by external market demands.

6. Contract Manufacturers: The current data does not provide evidence of contract manufacturers among the top buyers. These entities typically procure active pharmaceutical ingredients (APIs) rather than finished products like Ustekinumab.

Country-Specific Import Regulations

TransData Nexus Ustekinumab buyer market intelligence

1Country-Specific Import Regulations

Understanding the regulatory frameworks in the top importing countries is crucial for market entry and compliance.

1. Brazil:

Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA)

Import Registration Process: Importers must obtain a Sanitary License and Good Manufacturing Practice (GMP) certification. The registration process involves submitting a comprehensive dossier, including clinical data and labeling information.

Estimated Timeline: The registration process can take approximately 6 to 12 months, depending on the completeness of the application and ANVISA's review workload.

Import Tariff/Duty: Pharmaceutical products under HS Code 30021500 are generally subject to a 14% import duty, though specific rates may vary based on trade agreements and product classifications.

2. Japan:

Regulatory Authority: Pharmaceuticals and Medical Devices Agency (PMDA)

Demand Drivers & Market Opportunity

TransData Nexus Ustekinumab buyer market intelligence

1Demand Drivers & Market Opportunity

The demand for Ustekinumab in importing countries is driven by several key factors:

1. Disease Prevalence: Ustekinumab is primarily used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn's disease. The increasing incidence of these conditions, particularly in countries like Brazil and Japan, fuels demand for effective biologic therapies.

2. Government Healthcare Programs: Many importing countries have implemented healthcare initiatives aimed at improving access to advanced treatments. For instance, Saudi Arabia's Vision 2030 includes reforms to enhance healthcare services, potentially increasing the adoption of biologics like Ustekinumab.

3. Universal Health Coverage Expansion: Countries such as Turkey and the UAE are expanding their healthcare coverage, leading to greater accessibility and affordability of specialty medications.

4. WHO Essential Medicines List Procurement: While Ustekinumab is not currently listed on the WHO Essential Medicines List, its inclusion in national formularies can influence procurement decisions, especially in countries aligning their healthcare policies with WHO recommendations.

5. Tender-Based Purchasing: Government tenders and bulk purchasing agreements are common in markets like Brazil and Saudi Arabia, facilitating large-scale procurement of biologics to meet public health needs.

Our data, encompassing 78 buyers across 10 countries, underscores the diverse and expanding market for Ustekinumab. The combination of rising disease prevalence, supportive government policies, and evolving healthcare infrastructures presents significant opportunities for market growth and penetration.

Common Questions — Ustekinumab Buyers & Importers

Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus

QWho is the largest ustekinumab buyer importing from India?

Based on import volume and value, AS PER INVOICE BRAZIL (BRAZIL) leads with $112.2K in imports and a 8.8% market share — the highest of any single ustekinumab importer. SHIMA HIROMI (JAPAN) and TO THE CONCERN PERSON (BRAZIL) are the next largest buyers.

QHow many companies buy ustekinumab from India?

There are 78 active ustekinumab buyers importing from India, with a combined market of $1.3M across 276 shipments to 10 countries. The top 5 buyers hold 27.5% of total import value, while the remaining 73 buyers handle the other 72.5%.

QWhich countries import the most ustekinumab from India?

The top importing countries for ustekinumab from India are Brazil (71.5%), Japan (12.6%), Saudi Arabia (9.9%), Turkey (2.9%), United Arab Emirates (1.5%). These markets represent the largest demand centres for Indian pharmaceutical exports of ustekinumab, with buyers ranging from government procurement agencies to private pharmaceutical distributors.

Buyer Segment Analysis

TransData Nexus Ustekinumab buyer market intelligence

1Buyer Segment Analysis

Buyer Segments:

Country-Specific Import Regulations

TransData Nexus Ustekinumab buyer market intelligence

1Country-Specific Import Regulations

Understanding the regulatory frameworks in the top importing countries is crucial for market entry and compliance.

1. Brazil:

Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA)

Import Registration Process: Importers must obtain a Sanitary License and Good Manufacturing Practice (GMP) certification. The registration process involves submitting a comprehensive dossier, including clinical data and labeling information.

Estimated Timeline: The registration process can take approximately 6 to 12 months, depending on the completeness of the application and ANVISA's review workload.

Import Tariff/Duty: Pharmaceutical products under HS Code 30021500 are generally subject to a 14% import duty, though specific rates may vary based on trade agreements and product classifications.

2. Japan:

Regulatory Authority: Pharmaceuticals and Medical Devices Agency (PMDA)

Demand Drivers & Market Opportunity

TransData Nexus Ustekinumab buyer market intelligence

1Demand Drivers & Market Opportunity

The demand for Ustekinumab in importing countries is driven by several key factors:

3. Universal Health Coverage Expansion: Countries such as Turkey and the UAE are expanding their healthcare coverage, leading to greater accessibility and affordability of specialty medications.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Ustekinumab

Ustekinumab

Who Buys Ustekinumab from India — 78 Importers Behind a $1.3M Market

Top Ustekinumab Importers — Ranked by Import Value

Top Ustekinumab Buyers & Importers

Related Analysis

Need Details?

Market Analysis: Top Importing Countries & Importers

Which companies are buying Ustekinumab — and from which countries?

Ustekinumab — Buyer Countries to Key Importers

Market Analysis: Top Importing Countries & Their Importers

1Brazil

Buyer Segment Analysis

1Buyer Segment Analysis

Country-Specific Import Regulations

1Country-Specific Import Regulations

Demand Drivers & Market Opportunity

1Demand Drivers & Market Opportunity

Common Questions — Ustekinumab Buyers & Importers

QWho is the largest ustekinumab buyer importing from India?

QHow many companies buy ustekinumab from India?

QWhich countries import the most ustekinumab from India?

Buyer Segment Analysis

1Buyer Segment Analysis

Country-Specific Import Regulations

1Country-Specific Import Regulations

Demand Drivers & Market Opportunity

1Demand Drivers & Market Opportunity

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

2Japan

3Saudi Arabia

4Turkey

5United Arab Emirates

QWhat is the average import order value for ustekinumab from India?

Analysis Methodology